Review summary
Teaching objective: Work up hoarseness from left vocal fold paralysis in a 63-year-old former heavy smoker to a tissue diagnosis of advanced nonsquamous non-small cell lung cancer; stage it with PET-CT and brain MRI; obtain PD-L1 and comprehensive tissue and plasma biomarker testing before choosing first-line systemic therapy (pembrolizumab for PD-L1 70 percent with no actionable alteration); monitor for immune-related adverse events with TSH, free T4, liver tests, glucose, and cortisol as indicated, and evaluate a rash on treatment; start a bone-modifying agent safely; integrate palliative care early (ASCO 2017) with symptom and distress screening; record the tobacco history; begin advance care planning; and support his wish to keep performing, on the CMID lung cancer schedule and NCCN guidance.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| July 11, 1920 | Born in Vladivostok, by the documented account; he later gave other birthplaces and years. | CLM-0001, CLM-0002 |
| 1951 | First plays the King in The King and I on Broadway; Academy Award for the 1956 film. | CLM-0003 |
| 1971 | Quits smoking after decades of heavy use. | CLM-0004 |
| September 1983 | Found to have lung cancer that cannot be removed surgically; treated that month and vows to resume touring. | CLM-0005 |
| summer 1985 | Last performance as the King in New York, about two years after the diagnosis. | CLM-0006, CLM-0007 |
| October 10, 1985 | Dies in New York at 65 of complications of cancer; an anti-smoking message he recorded is broadcast after his death. | CLM-0008, CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Yul Brynner was born Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, Russia. The documented date used for the synthetic date of birth; it agrees with his age of 65 at death in contemporary obituaries. He gave other accounts himself (see CLM-0002). |
probable | Yul Brynner supports Yul Brynner, exotic actor (obituary) supports Milestones, Oct. 21, 1985 supports |
| D | He gave varying accounts of his origins, saying at times that he was born on Sakhalin Island, with the year given as 1915 (UPI gives July 11, 1915; another reference gives July 12, 1915, under the name Taidje Kahn). The conflicting accounts are his own; they are recorded as rejected alternatives to the documented date. |
confirmed | Yul Brynner, exotic actor (obituary) supports Brynner's final bow supports Brynner, Yul supports Milestones, Oct. 21, 1985 supports |
| D | He first played the King of Siam in The King and I on Broadway in 1951, won the Academy Award for best actor in the 1956 film, and played the role 4,625 times over 34 years. Used for the synthetic modern occupation (stage actor and singer on tour). |
confirmed | Yul Brynner supports Milestones, Oct. 21, 1985 supports Yul Brynner, exotic actor (obituary) supports |
| D | He smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971. The amounts differ between sources; the quit year is from one source. Used for the former-smoker history; the pack-year estimate in the modern record is synthetic. |
probable | Brynner's final bow supports 'Don't smoke, whatever you do' supports Rochman S. Yul Brynner (Cancer Today) supports |
| D | In September 1983 he was found to have lung cancer; Cancer Today reports that he had found a lump on his vocal cords and that the tumor was too close to his heart for surgery, and UPI reports that he was treated for lung cancer that month and said he would beat the disease and resume touring. The diagnosis month and the inoperable tumor are consistent across sources; the voice complaint and the place of treatment are from single sources. Anchors the synthetic presentation with hoarseness and an unresectable left upper lobe cancer. |
probable | Rochman S. Yul Brynner (Cancer Today) supports Yul Brynner, exotic actor (obituary) supports |
| D | He returned to the stage and kept playing the King for about two more years; his last performance came in New York in the summer of 1985, less than four months before his death. UPI gives July 2 for the farewell performance; other accounts give June 30. The case uses summer 1985. Used for the goal of supporting him to keep working. |
confirmed | Yul Brynner, exotic actor (obituary) supports Brynner's final bow supports Milestones, Oct. 21, 1985 supports |
| D | He said in an interview that he believed his cancer was directly caused by smoking, calling smoking "suicide." His own public statement. |
confirmed | Brynner's final bow supports |
| D | After his death the American Cancer Society released a 30-second television message taken from a January 1985 Good Morning America interview, in which he says: "Now that I'm gone, I tell you: Don't smoke, whatever you do. Just don't smoke." UPI reports that it first aired on ABC in February 1986, about four months after his death; Cancer Today says networks ran it within days of his death. The case records both and uses neither date in the episode. |
confirmed | 'Don't smoke, whatever you do' supports Rochman S. Yul Brynner (Cancer Today) supports Brynner, Yul supports |
| D | He died on October 10, 1985, at 65, at New York Hospital-Cornell Medical Center, of complications of cancer. History only; after the true-frame episode. |
confirmed | Yul Brynner, exotic actor (obituary) supports Yul Brynner supports Milestones, Oct. 21, 1985 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
| S | Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | active | CLM-0005, CLM-0006 |
| S | Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | both_with_link | CLM-0005 |
| S | Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | active | CLM-0005, CLM-0006 |
| S | Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | both_with_link | CLM-0004, CLM-0007 |
| S | Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement) | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-09-01 | Hemoglobin [Mass/volume] in Blood | 13.8 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-09-01 | Leukocytes [#/volume] in Blood by Automated count | 7.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-09-01 | Platelets [#/volume] in Blood by Automated count | 290 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-09-01 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-09-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-09-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 92 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-01 | Calcium [Mass/volume] in Serum or Plasma | 9.6 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-09-01 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-09-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-09-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-09-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-09-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-09-01 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-09-15 | Total score [Edmonton Symptom Assessment System] | 18 | http://loinc.org · 112493-2 |
| S | 2026-09-22 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-09-22 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-09-22 | Cortisol [Mass/volume] in Serum or Plasma | 14.2 ug/dL Reference Morning (8 a.m.) reference interval |
http://loinc.org · 2143-6 |
| S | 2026-09-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-09-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-09-22 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 101 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 2026-09-22 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-09-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 92 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-22 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-22 | Calcium [Mass/volume] in Serum or Plasma | 9.5 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-09-22 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-09-22 | Leukocytes [#/volume] in Blood by Automated count | 7.6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-09-22 | Platelets [#/volume] in Blood by Automated count | 284 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-10-13 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-10-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-10-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 92 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-13 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-10-13 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-10-13 | Hemoglobin [Mass/volume] in Blood | 13.5 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-13 | Leukocytes [#/volume] in Blood by Automated count | 7.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-13 | Platelets [#/volume] in Blood by Automated count | 270 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-13 | Total score [Edmonton Symptom Assessment System] | 12 | http://loinc.org · 112493-2 |
| S | 2026-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-20 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-10-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-10-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-20 | Eosinophils [#/volume] in Blood by Automated count | 0.62 10*3/uL (high) Reference 0-0.5 10*3/uL |
http://loinc.org · 711-2 |
| S | 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-10-27 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-09-01 | Body height | 178 cm | 8302-2 | S |
| 2026-09-01 | Body weight | 72.4 kg | 29463-7 | S |
| 2026-09-01 | Body mass index (BMI) [Ratio] | 22.9 kg/m2 | 39156-5 | S |
| 2026-09-01 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-09-01 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-09-01 | Heart rate | 82 /min | 8867-4 | S |
| 2026-09-01 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-01 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-09-15 | Body height | 178 cm | 8302-2 | S |
| 2026-09-15 | Body weight | 72 kg | 29463-7 | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.7 kg/m2 | 39156-5 | S |
| 2026-09-15 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-09-15 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-09-15 | Heart rate | 80 /min | 8867-4 | S |
| 2026-09-15 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-15 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-09-22 | Body height | 178 cm | 8302-2 | S |
| 2026-09-22 | Body weight | 71.8 kg | 29463-7 | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 22.7 kg/m2 | 39156-5 | S |
| 2026-09-22 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-09-22 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-09-22 | Heart rate | 78 /min | 8867-4 | S |
| 2026-09-22 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-22 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-10-13 | Body height | 178 cm | 8302-2 | S |
| 2026-10-13 | Body weight | 72.2 kg | 29463-7 | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.8 kg/m2 | 39156-5 | S |
| 2026-10-13 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-10-13 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-13 | Heart rate | 76 /min | 8867-4 | S |
| 2026-10-13 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-13 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-20 | Body height | 178 cm | 8302-2 | S |
| 2026-10-20 | Body weight | 72 kg | 29463-7 | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 22.7 kg/m2 | 39156-5 | S |
| 2026-10-20 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-10-20 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-10-20 | Heart rate | 78 /min | 8867-4 | S |
| 2026-10-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-20 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-27 | Body height | 178 cm | 8302-2 | S |
| 2026-10-27 | Body weight | 72.3 kg | 29463-7 | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.8 kg/m2 | 39156-5 | S |
| 2026-10-27 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-10-27 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-27 | Heart rate | 74 /min | 8867-4 | S |
| 2026-10-27 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Former smoker: about 3 packs a day from age 12 until he quit 12 years ago (roughly 115 pack-years); no tobacco, vaping, or cannabis since; wants other smokers to hear his story
- S Alcohol: a glass of wine with dinner two or three nights a week (AUDIT-C 2); no other drug use
- S Stage actor and singer, leading a national touring production with eight performances a week; has paused the tour for the tests and wants to return as soon as he safely can
- S Married; lives in an apartment in New York and on the road during the tour; a company manager and a long-time dresser help with the travel schedule
- S No occupational asbestos, radon, or diesel exposure known; no family history of lung cancer known to him
Functional status
- S ECOG performance status 1: fully active offstage, but tires by the end of an evening and has stopped singing because of the weak voice; walks briskly without breathlessness on the level; climbs two flights with mild breathlessness
Mental status
- S Alert, commanding, and precise; wants the facts plainly and in full
- S Worried but composed; PHQ-9 score 5 with item 9 scored 0; no thoughts of suicide or self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks
- S Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases
- S Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid
- S Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds)
- S Cetirizine 10 mg oral tablet, one tablet daily as needed for itching
Procedures and immunizations
Procedures
- S Flexible laryngoscopy by the ENT surgeon: left vocal fold immobile in the paramedian position with incomplete glottic closure; no laryngeal mass or mucosal lesion
- S CT of the chest, abdomen, and pelvis with contrast: 5.2 cm left upper lobe mass invading the mediastinal fat of the aortopulmonary window and abutting the aortic arch and left pulmonary artery; enlarged aortopulmonary window (2.4 cm) and subcarinal (1.8 cm) lymph nodes; a small lytic lesion in the T10 vertebral body; no adrenal or liver lesion
- S FDG PET-CT: avid left upper lobe mass (SUVmax 14) with mediastinal invasion; avid aortopulmonary window and subcarinal nodes (N2); no contralateral or supraclavicular nodes; avid lytic lesions at T10, the right ilium, and the left sixth rib, without fracture (M1c)
- S MRI of the brain with contrast: no metastases
- S Endobronchial ultrasound-guided needle aspiration of subcarinal (station 7) and left lower paratracheal (4L) nodes: adenocarcinoma, TTF-1 and napsin A positive; PD-L1 (22C3) tumor proportion score 70 percent; tissue sent for comprehensive next-generation sequencing (reported 12 days later: KRAS G12V and TP53 mutations; no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration), with concordant plasma cell-free DNA testing
- S Outpatient palliative care visit: symptom assessment, coping, goals of care, and a plan for breathlessness and cough
- S Office injection medialization of the left vocal fold under laryngoscopic guidance by the ENT surgeon, to improve glottic closure and voice
- S Advance care planning conversation, about 30 minutes
Immunizations
- S 2025-10-21: Influenza vaccine, 2025-2026 season
- S 2020-03-17: Tdap vaccine
- S 2026-10-27: Influenza vaccine, 2026-2027 season
- S 2026-10-27: Pneumococcal conjugate vaccine PCV20, single dose
- S 2026-10-27: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1971: Heavy cigarette smoking for decades, quit twelve years before the index visit (CLM-0004)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation | 2026-09-22 | completed | Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed |
| First palliative care visit within eight weeks of diagnosis | 2026-10-13 | completed | Seen by the palliative care team two weeks after diagnosis |
| A voice strong enough for rehearsal by the second cycle | 2026-10-13 | completed | Louder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy |
| No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit | 2026-10-13 | completed | Panels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction |
| Zoledronic acid started only after a dental examination and normal calcium and kidney function | 2026-10-13 | completed | Dental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
| Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
| First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stable | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
| Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone line | completed | GL-ASCO-IRAE-2021, GL-CMID-2026 |
| Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planning | completed | GL-ASCO-PALL-2017, GL-NCCN-DISTRESS-2026, GL-CMID-2026 |
| If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
| Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he chooses | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
| Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 |
Planned encounters
- 2026-09-01 — New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT (ENC-001)
- 2026-09-15 — Diagnosis and staging review with thoracic oncology consultation (ENC-002)
- 2026-09-22 — Biomarker results and start of first-line pembrolizumab (ENC-003)
- 2026-10-13 — Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work (ENC-004)
- 2026-10-20 — Same-day sick visit for an itchy rash on pembrolizumab (ENC-005, unscheduled)
- 2026-10-27 — Periodic adult preventive visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Care-plan review)
- Progress note 05 — Sick Visit
- Progress note 06 — Preventive Visit
- Thoracic Oncology referral
- Thoracic Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Care-plan review) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Preventive Visit (XML)
- Thoracic Oncology referral (XML)
- Thoracic Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Yul Brynner, exotic actor (obituary) | United Press International | other |
| SRC-0002 | Brynner's final bow | United Press International | other |
| SRC-0003 | 'Don't smoke, whatever you do' | United Press International | other |
| SRC-0004 | Rochman S. Yul Brynner (Cancer Today) | American Association for Cancer Research | other |
| SRC-0005 | Milestones, Oct. 21, 1985 | TIME | other |
| SRC-0006 | Yul Brynner | Biography.com (A&E Television Networks) | biography |
| SRC-0007 | Brynner, Yul | Encyclopedia.com (International Dictionary of Films and Filmmakers) | biography |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the stage, the biomarker sequence (therapy started only after tissue sequencing), the choice of pembrolizumab monotherapy, the immune-related adverse event monitoring, the rash evaluation at the sick visit, and the deviation recorded for the missed symptom screen at treatment start. |
| provenance review | not_started | The recent-death rule does not apply (died 1985). Historical claims come from UPI, TIME, Cancer Today (AACR), Biography.com, and Encyclopedia.com. Birth-date conflicts from his own accounts are recorded as rejected alternatives. No statement or health fact is attributed to his relatives or colleagues; the histology, stage, biomarkers, and treatment are synthetic. |
| safe messaging review | not_started | Tobacco claims are marked sensitive; his death is recorded without detail; the anti-smoking message is quoted as published. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.